Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

647 public trials 86 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Boca Raton Clinical Research (BRCR) Global Plantation, Florida, United States
  • Indiana University and Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Hattiesburg Clinic Hattiesburg, Mississippi, United States
View all 171 locations
View Trial Details
Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations
  • LLC ARENSIA Exploratory Medicine Tbilisi, Georgia
  • IMSP Institute of Oncology, ARENSIA Exploratory Medicine Chisinau, Moldova
  • Hospital Beata Maria Ana Madrid, Spain
  • Hospital Fundación Jiménez Diaz Madrid, Spain
View all 17 locations
View Trial Details
Recruiting

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT06533579

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Chronic Disease, +40 more
Locations
  • City of Hope Duarte, California, United States
  • Valkyrie Clinical Trials Los Angeles, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • New York Medical College Valhalla, New York, United States
View Trial Details
Recruiting

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

NCT06708897

Conditions
Blood Protein Disorders, CLL (Chronic Lymphocytic Leukemia), CLL / SLL, +32 more
Locations
  • Norton Cancer Institute, St. Matthews Campus Louisville, Kentucky, United States
  • University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
  • University of Cincinnati Cincinnati, Ohio, United States
  • The Ohio State University Columbus, Ohio, United States
View Trial Details
Recruiting

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

NCT07424833

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +33 more
Locations
  • Mayo Clinic Jacksonville, Florida, United States
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • START Los Angele Los Angeles, California, United States
  • START Midwest Grand Rapids, Michigan, United States
View Trial Details
Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT07121946

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Follicular Lymphoma ( FL), +18 more
Locations
  • City of Hope Duarte, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center - Bergen New York, United States
View Trial Details

Related conditions